Expert Liver, Bile Duct & Pancreatic Cancer Surgery in Shanghai
The Department of Hepatobiliary and Pancreatic Surgery at Fudan University Shanghai Cancer Center (FUSCC) is one of China's most distinguished centers for the surgical and multidisciplinary management of hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, gallbladder cancer, pancreatic cancer, and liver metastases from colorectal and other primary cancers. The department combines outstanding surgical expertise with a world-class research program and a fully integrated multidisciplinary approach, offering international patients access to the latest minimally invasive techniques, precision oncology, and clinical trials for hepatobiliary and pancreatic cancers.
For international patients with liver, bile duct, or pancreatic cancer — whether seeking surgical treatment, a second opinion, or access to novel targeted therapies and immunotherapy — FUSCC's hepatobiliary and pancreatic surgery department offers an unparalleled combination of expertise, volume, and research leadership. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their care journey at FUSCC.
About the Department
FUSCC's hepatobiliary and pancreatic surgery department is a national key clinical specialty performing hundreds of major hepatobiliary and pancreatic cancer operations annually. The department operates dedicated surgical wards, a comprehensive outpatient hepatobiliary oncology clinic, a hepatobiliary and pancreatic cancer MDT, a minimally invasive and robotic surgical program, and works in close collaboration with interventional radiology, medical oncology, radiation oncology, pathology, and molecular diagnostics through a fully integrated multidisciplinary team.
Faculty members publish regularly in leading hepatobiliary and pancreatic oncology journals including Journal of Clinical Oncology, Annals of Surgery, Hepatology, Journal of Hepatology, Annals of Surgical Oncology, and Pancreatology.
Conditions Treated
Hepatocellular Carcinoma (HCC)
- Resectable HCC — Anatomical and non-anatomical hepatic resection; laparoscopic and robotic liver resection; major hepatectomy (hemihepatectomy, trisectionectomy); vascular resection and reconstruction for tumors with portal vein or hepatic vein involvement
- Borderline Resectable HCC — Portal vein embolization (PVE) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) to increase future liver remnant; conversion therapy with TACE, HAIC, or systemic therapy to enable resection
- Early HCC — Surgical resection vs. ablation (RFA, MWA) decision-making; laparoscopic ablation for deep lesions
- Advanced HCC — Atezolizumab + bevacizumab (IMbrave150); sintilimab + bevacizumab; lenvatinib; sorafenib; TACE and HAIC coordination; regorafenib and cabozantinib second-line; ramucirumab for AFP ≥400
- HCC with Portal Vein Tumor Thrombus (PVTT) — Surgical resection with thrombectomy for selected patients; HAIC + lenvatinib conversion therapy
- Fibrolamellar HCC — Surgical resection; systemic therapy for advanced disease
Cholangiocarcinoma
- Intrahepatic Cholangiocarcinoma (iCCA) — Hepatic resection with adequate margins; lymph node dissection; adjuvant capecitabine; IDH1 inhibitors (ivosidenib) for IDH1-mutated iCCA; FGFR2 inhibitors (pemigatinib, infigratinib, futibatinib) for FGFR2-fused iCCA; durvalumab + gemcitabine + cisplatin
- Perihilar Cholangiocarcinoma (Klatskin Tumor) — Extended hepatectomy with bile duct resection and reconstruction; portal vein resection for vascular involvement; preoperative biliary drainage; liver transplantation for selected unresectable perihilar CCA
- Distal Cholangiocarcinoma — Pancreaticoduodenectomy (Whipple procedure); adjuvant gemcitabine + cisplatin
- Gallbladder Cancer — Extended cholecystectomy with hepatic resection and lymph node dissection; adjuvant capecitabine; durvalumab + gemcitabine + cisplatin for advanced disease
- Ampullary Cancer — Pancreaticoduodenectomy; adjuvant chemotherapy
Pancreatic Cancer
- Resectable Pancreatic Ductal Adenocarcinoma (PDAC) — Pancreaticoduodenectomy (Whipple procedure) and distal pancreatectomy; vascular resection and reconstruction for borderline resectable disease; adjuvant FOLFIRINOX or gemcitabine + capecitabine
- Borderline Resectable PDAC — Neoadjuvant FOLFIRINOX or gemcitabine + nab-paclitaxel; restaging and conversion surgery; vascular resection and reconstruction
- Locally Advanced PDAC — FOLFIRINOX conversion therapy; SBRT consolidation; surgical resection for exceptional responders
- Metastatic PDAC — FOLFIRINOX; gemcitabine + nab-paclitaxel; PARP inhibitors (olaparib) for BRCA-mutated; KRAS G12C inhibitors in clinical trials; NTRK inhibitors for NTRK-fused
- Pancreatic Neuroendocrine Tumors (PNETs) — Surgical resection; somatostatin analogues; PRRT; everolimus; sunitinib
- Intraductal Papillary Mucinous Neoplasm (IPMN) — Risk stratification and surgical resection for high-risk features
- Cystic Pancreatic Tumors — MCN, SPN, and serous cystadenoma; surveillance and surgical management
Liver Metastases
- Colorectal Liver Metastases (CRLM) — Hepatic resection with curative intent; two-stage hepatectomy; portal vein embolization; ALPPS; conversion chemotherapy for initially unresectable CRLM; HAI pump coordination
- Neuroendocrine Liver Metastases — Cytoreductive hepatic resection; TACE; PRRT
- Non-Colorectal, Non-Neuroendocrine Liver Metastases — Selected resection for breast, gastric, and other primaries
Minimally Invasive & Robotic Hepatobiliary Surgery
FUSCC's hepatobiliary surgery department has been at the forefront of minimally invasive liver and pancreatic surgery in China:
- Laparoscopic Liver Resection — Minor and major laparoscopic hepatectomy; laparoscopic anatomical segmentectomy; reduced blood loss and faster recovery
- Robotic Liver Resection — da Vinci robotic hepatectomy for posterosuperior segments and complex resections
- Laparoscopic Whipple Procedure — Fully laparoscopic pancreaticoduodenectomy for selected patients
- Robotic Whipple Procedure — Robotic pancreaticoduodenectomy for enhanced precision in reconstruction
- Laparoscopic Distal Pancreatectomy — Standard of care for body and tail pancreatic tumors; spleen-preserving techniques
- Robotic Distal Pancreatectomy — For tumors requiring spleen preservation or in difficult locations
Interventional Oncology Integration
FUSCC's hepatobiliary oncology program is closely integrated with interventional radiology for locoregional therapies:
- TACE (Transarterial Chemoembolization) — Conventional and drug-eluting bead TACE for HCC; bridge to surgery or transplantation
- HAIC (Hepatic Arterial Infusion Chemotherapy) — FOLFOX-HAIC for advanced HCC with PVTT; conversion therapy for initially unresectable HCC
- Thermal Ablation — RFA and MWA for small HCC and liver metastases; laparoscopic and CT-guided approaches
- SIRT (Selective Internal Radiation Therapy) — Y-90 radioembolization for HCC and liver metastases
- Portal Vein Embolization (PVE) — Pre-operative liver volume augmentation for major hepatectomy
Why International Patients Choose FUSCC Hepatobiliary & Pancreatic Surgery
- HCC Surgical Expertise — Complex hepatic resection including vascular involvement, ALPPS, and conversion surgery after locoregional therapy
- Cholangiocarcinoma Leadership — Perihilar CCA surgery and IDH1/FGFR2-targeted therapy for advanced iCCA
- Pancreatic Cancer Program — Borderline resectable PDAC conversion surgery and vascular resection
- Minimally Invasive Expertise — Laparoscopic and robotic liver and pancreatic surgery as routine offerings
- Integrated Interventional Oncology — TACE, HAIC, ablation, and SIRT seamlessly integrated with surgical planning
- Cost-Effectiveness — World-class hepatobiliary cancer care at significantly lower cost than equivalent treatment in Western countries
The CMCS Patient Journey
- Initial Inquiry — Share your diagnosis, imaging (CT, MRI, PET-CT), biopsy pathology, molecular profiling, tumor markers (AFP, CA19-9, CEA), and prior treatment history with CMCS.
- Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
- Specialist Matching — We identify the most appropriate hepatobiliary surgeon based on your tumor type — HCC, cholangiocarcinoma, pancreatic cancer, or liver metastases.
- MDT Submission — Where appropriate, we facilitate pre-arrival case review by FUSCC's hepatobiliary and pancreatic cancer MDT.
- Priority Scheduling — We secure a consultation and surgical slot with minimal waiting time.
- Travel & Logistics — Assistance with visa invitation letters, accommodation near FUSCC, and Shanghai airport transfers.
- Surgical Admission Support — Full coordination of pre-operative assessment, conversion therapy scheduling if required, admission, and inpatient care.
- Post-Operative Follow-Up — Pathology and molecular profiling report translation, adjuvant therapy coordination, and remote follow-up after you return home.
Book a Consultation
If you are seeking expert hepatobiliary or pancreatic cancer care in Shanghai — whether for liver cancer, bile duct cancer, pancreatic cancer, liver metastases, or a second opinion on a complex hepatobiliary diagnosis — CMCS can arrange a specialist consultation with FUSCC's hepatobiliary and pancreatic surgery team.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
댓글 0개